Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
• The report provides competitivepipeline landscape of Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura)
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Idiopathic Thrombocytopenic Purpura (Immune Thombocytopenic Purpura) and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Idiopathic...

血栓性血小板減少性紫斑(Thrombotic Thrombocytopenic Purpura)：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Thrombotic Thrombocytopenic Purpura-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Thrombotic Thrombocytopenic Purpura. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Thrombotic Thrombocytopenic Purpura. DelveInsight’s Report also assesses...

特発性(本態性)高血圧症(Idiopathic (Essential) Hypertension)：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Idiopathic (Essential) Hypertension-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic (Essential) Hypertension. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Idiopathic (Essential) Hypertension. DelveInsight’s Report also assesses...

特発性肺線維症(Idiopathic Pulmonary Fibrosis)：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Idiopathic Pulmonary Fibrosis-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Pulmonary Fibrosis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Idiopathic Pulmonary Fibrosis. DelveInsight’s Report also assesses...

特発性小人症(Idiopathic Short Stature)：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Idiopathic Short Stature-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Idiopathic Short Stature. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Idiopathic Short Stature. DelveInsight’s Report also assesses...

原発性免疫不全症(Primary Immune Deficiency (PID))：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Primary Immune Deficiency (PID)-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Primary Immune Deficiency (PID). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Primary Immune Deficiency (PID). DelveInsight’s...

全身型若年性特発性関節炎(SJIA)：治療薬開発パイプライン動向2018SUMMARY DelveInsight’s, “ Systemic Juvenile Idiopathic Arthritis (SJIA)-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Systemic Juvenile Idiopathic Arthritis (SJIA). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Systemic Juvenile Idiopathic...

特発性血小板減少性紫斑病（ITP）治療薬の世界市場：市場インサイト、疫学、市場予測Note*: This report requires 7-10 business days to complete. DelveInsight’s Idiopathic Thrombocytopenic Purpura (ITP) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Idiopathic Thrombocytopenic Purpura (ITP) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Idiopathic Thrombocytopenic Purpura (ITP) till 2023....